| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Matthew Harlin, Murat Yildirim, Pedro Such, Jessica Madera-McDonough, Michael Jan, Na Jin, Suzanne Watkin, Frank Larse. A Randomized, Open-Label, Multiple-Dose, Parallel-Arm, Pivotal Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Aripiprazole 2-Month Long-Acting Injectable in Adults With Schizophrenia or Bipolar I Disorder. CNS drugs. 2023-03-24. PMID:36961650. |
a randomized, open-label, multiple-dose, parallel-arm, pivotal study to evaluate the safety, tolerability, and pharmacokinetics of aripiprazole 2-month long-acting injectable in adults with schizophrenia or bipolar i disorder. |
2023-03-24 |
2023-08-14 |
Not clear |
| Matthew Harlin, Murat Yildirim, Pedro Such, Jessica Madera-McDonough, Michael Jan, Na Jin, Suzanne Watkin, Frank Larse. A Randomized, Open-Label, Multiple-Dose, Parallel-Arm, Pivotal Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Aripiprazole 2-Month Long-Acting Injectable in Adults With Schizophrenia or Bipolar I Disorder. CNS drugs. 2023-03-24. PMID:36961650. |
aripiprazole 2-month ready-to-use 960 mg (ari 2mrtu 960) is a new long-acting injectable antipsychotic formulation for gluteal administration every 2 months, currently being investigated for the treatment of schizophrenia and bipolar i disorder (bp-i). |
2023-03-24 |
2023-08-14 |
Not clear |
| Matthew Harlin, Murat Yildirim, Pedro Such, Jessica Madera-McDonough, Michael Jan, Na Jin, Suzanne Watkin, Frank Larse. A Randomized, Open-Label, Multiple-Dose, Parallel-Arm, Pivotal Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Aripiprazole 2-Month Long-Acting Injectable in Adults With Schizophrenia or Bipolar I Disorder. CNS drugs. 2023-03-24. PMID:36961650. |
the objectives of this trial were to evaluate the safety and tolerability of ari 2mrtu 960, and the similarity of aripiprazole plasma concentrations following administration of ari 2mrtu 960 or aripiprazole once-monthly 400 mg (aom 400), in adults with schizophrenia or bp-i. |
2023-03-24 |
2023-08-14 |
Not clear |
| Daniel Schöttle, Wolfgang Janetzky, Francois Therrien, Klaus Wiedeman. BPRS domains, items and subgroups analyses, and CGI-I ratings in pooled data from non-interventional studies of aripiprazole once-monthly in schizophrenia (REACT study). BMC psychiatry. vol 23. issue 1. 2023-03-15. PMID:36918846. |
bprs domains, items and subgroups analyses, and cgi-i ratings in pooled data from non-interventional studies of aripiprazole once-monthly in schizophrenia (react study). |
2023-03-15 |
2023-08-14 |
Not clear |
| Ruth Milz, Carmela Benson, Karl Knight, Jose Antunes, Dean Najarian, Paola-Maria Lopez Rengel, Steven Wang, Ute Richarz, Srihari Gopal, John M Kan. The Effect of Longer Dosing Intervals for Long-Acting Injectable Antipsychotics on Outcomes in Schizophrenia. Neuropsychiatric disease and treatment. vol 19. 2023-03-14. PMID:36915909. |
aripiprazole lauroxil and paliperidone palmitate three-monthly (pp3m) lais have longer dosing intervals of 2-3 months and provide improved outcomes in patients with schizophrenia. |
2023-03-14 |
2023-08-14 |
Not clear |
| Saki Hattori, Akira Suda, Ikuko Kishida, Masatoshi Miyauchi, Yohko Shiraishi, Nobuhiko Noguchi, Taku Furuno, Takeshi Asami, Mami Fujibayashi, Natsuki Tsujita, Chie Ishii, Norio Ishii, Takashi Saeki, Tadashi Fukushima, Toshio Moritani, Yusuke Saigusa, Akitoyo Hishimot. Differences in autonomic nervous system activity between long-acting injectable aripiprazole and oral aripiprazole in schizophrenia. BMC psychiatry. vol 23. issue 1. 2023-03-03. PMID:36869320. |
differences in autonomic nervous system activity between long-acting injectable aripiprazole and oral aripiprazole in schizophrenia. |
2023-03-03 |
2023-08-14 |
Not clear |
| Saki Hattori, Akira Suda, Ikuko Kishida, Masatoshi Miyauchi, Yohko Shiraishi, Nobuhiko Noguchi, Taku Furuno, Takeshi Asami, Mami Fujibayashi, Natsuki Tsujita, Chie Ishii, Norio Ishii, Takashi Saeki, Tadashi Fukushima, Toshio Moritani, Yusuke Saigusa, Akitoyo Hishimot. Differences in autonomic nervous system activity between long-acting injectable aripiprazole and oral aripiprazole in schizophrenia. BMC psychiatry. vol 23. issue 1. 2023-03-03. PMID:36869320. |
among them, oral aripiprazole has been linked to dysfunction of the ans in schizophrenia. |
2023-03-03 |
2023-08-14 |
Not clear |
| Saki Hattori, Akira Suda, Ikuko Kishida, Masatoshi Miyauchi, Yohko Shiraishi, Nobuhiko Noguchi, Taku Furuno, Takeshi Asami, Mami Fujibayashi, Natsuki Tsujita, Chie Ishii, Norio Ishii, Takashi Saeki, Tadashi Fukushima, Toshio Moritani, Yusuke Saigusa, Akitoyo Hishimot. Differences in autonomic nervous system activity between long-acting injectable aripiprazole and oral aripiprazole in schizophrenia. BMC psychiatry. vol 23. issue 1. 2023-03-03. PMID:36869320. |
in this study, we compared ans activity between oral aripiprazole and aripiprazole once-monthly (aom) in schizophrenia. |
2023-03-03 |
2023-08-14 |
Not clear |
| Heidi C Waters, Robert Stellhorn, Maelys Touya, Heather Fitzgerald, Sandipan Bhattacharjee, Leslie Citrom. The effects of early initiation of aripiprazole once-monthly on healthcare resource utilization and healthcare costs in individuals with schizophrenia: real-world evidence from US claims data. Journal of medical economics. 2023-02-13. PMID:36780296. |
the effects of early initiation of aripiprazole once-monthly on healthcare resource utilization and healthcare costs in individuals with schizophrenia: real-world evidence from us claims data. |
2023-02-13 |
2023-08-14 |
Not clear |
| Heidi C Waters, Robert Stellhorn, Maelys Touya, Heather Fitzgerald, Sandipan Bhattacharjee, Leslie Citrom. The effects of early initiation of aripiprazole once-monthly on healthcare resource utilization and healthcare costs in individuals with schizophrenia: real-world evidence from US claims data. Journal of medical economics. 2023-02-13. PMID:36780296. |
to evaluate the impact of timing of aripiprazole once-monthly (aom) initiation on healthcare resource utilization (hcru), risk of hospitalization, and healthcare costs in patients with schizophrenia. |
2023-02-13 |
2023-08-14 |
Not clear |
| Chittaranjan Andrad. Prolactin-Raising and Prolactin-Sparing Antipsychotic Drugs and the Risk of Fracture and Fragility Fracture in Patients With Schizophrenia, Dementia, and Other Disorders. The Journal of clinical psychiatry. vol 84. issue 1. 2023-02-01. PMID:36724110. |
an observational study that controlled for confounding by indication and illness severity found that fragility fractures in patients with schizophrenia were associated with higher daily doses, higher cumulative doses, longer duration of treatment, and prolactin-raising rather than prolactin-sparing antipsychotics; in patients receiving prolactin-raising antipsychotics, the concurrent use of aripiprazole appeared protective. |
2023-02-01 |
2023-08-14 |
Not clear |
| Yusuke Okada, Ken Inada, Manabu Akazaw. Comparative effectiveness of long-acting injectable antipsychotics in patients with schizophrenia in Japan. Schizophrenia research. vol 252. 2023-01-27. PMID:36706475. |
to compare the effectiveness of different long-acting injectable antipsychotics (lais) (aripiprazole, paliperidone, risperidone, and fluphenazine/haloperidol) in patients with schizophrenia in japan. |
2023-01-27 |
2023-08-14 |
Not clear |
| Sung-Wan Kim, Bong-Ju Lee, Eun-Jin Cheon, Seung-Hee Won, Anna Jo, Jae-Min Kim, Young-Chul Chun. Effectiveness of Switching to Long-acting Injectable Aripiprazole in Patients with Recent-onset and Chronic Schizophrenia. Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology. vol 21. issue 1. 2023-01-26. PMID:36700312. |
effectiveness of switching to long-acting injectable aripiprazole in patients with recent-onset and chronic schizophrenia. |
2023-01-26 |
2023-08-14 |
Not clear |
| Sung-Wan Kim, Bong-Ju Lee, Eun-Jin Cheon, Seung-Hee Won, Anna Jo, Jae-Min Kim, Young-Chul Chun. Effectiveness of Switching to Long-acting Injectable Aripiprazole in Patients with Recent-onset and Chronic Schizophrenia. Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology. vol 21. issue 1. 2023-01-26. PMID:36700312. |
this study investigated the effectiveness of switching to once-monthly long-acting injectable (lai) aripiprazole from other second-generation antipsychotics including lai paliperidone palmitate in both recent-onset and chronic schizophrenia patients. |
2023-01-26 |
2023-08-14 |
Not clear |
| Ahmed M Abdelfattah, Sally A Abuelezz, Nevien Hendawy, Eman A Negm, Salwa Abd El Khalek Nawishy, Ahmed Mohamed Mohamed Khali. Sonic hedgehog pathway as a new target of atypical antipsychotics: Revisiting of amisulpride and aripiprazole effects in a rat model of schizophrenia. Life sciences. 2023-01-17. PMID:36649751. |
sonic hedgehog pathway as a new target of atypical antipsychotics: revisiting of amisulpride and aripiprazole effects in a rat model of schizophrenia. |
2023-01-17 |
2023-08-14 |
rat |
| Ahmed M Abdelfattah, Sally A Abuelezz, Nevien Hendawy, Eman A Negm, Salwa Abd El Khalek Nawishy, Ahmed Mohamed Mohamed Khali. Sonic hedgehog pathway as a new target of atypical antipsychotics: Revisiting of amisulpride and aripiprazole effects in a rat model of schizophrenia. Life sciences. 2023-01-17. PMID:36649751. |
in this study, effects of the anti-psychotics amisulpride and/or aripiprazole on the shh-pathway and its relation to cognitive functions and neurogenesis in a rat model of schizophrenia were tested. |
2023-01-17 |
2023-08-14 |
rat |
| Alessandro Cuomo, Eugenio Aguglia, Stefano Biagini, Alessandro Carano, Massimo Clerici, Armando D'Agostino, Sergio De Filippis, Serafino De Giorgi, Arianna Goracci, Claudia Libri, Francesco Lombardi, Matteo Lupi, Giuseppe Maina, Giovanni Martinotti, Pietro Nigro, Mauro Pettorruso, Valerio Ricci, Eros Rossi, Felicia Russo, Andrea Fagiolin. Two-Injection Start Regimen of Long-Acting Aripiprazole in 133 Patients With Schizophrenia. Journal of clinical psychopharmacology. vol 43. issue 1. 2022-12-30. PMID:36584247. |
two-injection start regimen of long-acting aripiprazole in 133 patients with schizophrenia. |
2022-12-30 |
2023-08-14 |
Not clear |
| I Yu Dorozheno. [Modern possibilities of anti-relapse therapy of schizophrenia (experience with the use of aripiprazole)]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. vol 122. issue 12. 2022-12-20. PMID:36537633. |
[modern possibilities of anti-relapse therapy of schizophrenia (experience with the use of aripiprazole)]. |
2022-12-20 |
2023-08-14 |
Not clear |
| I Yu Dorozheno. [Modern possibilities of anti-relapse therapy of schizophrenia (experience with the use of aripiprazole)]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. vol 122. issue 12. 2022-12-20. PMID:36537633. |
according to numerous studies, aripiprazole, due to its unique pharmacological profile and combination of clinical factors, is the drug of first choice for anti-relapse supportive therapy of schizophrenia. |
2022-12-20 |
2023-08-14 |
Not clear |
| Zhizhong Xu, Chunyan Wen, Yinghua Huang, Qianfa Yuan, Xianhua Zhang, Duoduo Lin, Liangsheng Liu, Wenqiang Wan. Effects of Glycogen Synthase Kinase-3 Beta Gene Polymorphisms on the Plasma Concentration of Aripiprazole in Chinese Patients with Schizophrenia: A Preliminary Study. Journal of molecular neuroscience : MN. 2022-12-20. PMID:36539584. |
effects of glycogen synthase kinase-3 beta gene polymorphisms on the plasma concentration of aripiprazole in chinese patients with schizophrenia: a preliminary study. |
2022-12-20 |
2023-08-14 |
Not clear |